Organon & Co.
OGN
Rank in Stocks
#4358
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Share Price
$13.75
Last synced: 2026-10-19
Market Cap
$3.61B
Change (1 day)
-0.11%
Change (1 year)
48.76%
Country
US
Trade Organon & Co. (OGN)
Category
Healthcare
P/E ratio for Organon & Co. (OGN)
P/E ratio as of October 2026 TTM: 17.39
According to Organon & Co. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.39. At the end of 2023 the company had a P/E ratio of 3.60.
P/E ratio history for Organon & Co. from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 17.39 | 291.72% |
| 2024 | 4.44 | 23.38% |
| 2023 | 3.60 | -53.51% |
| 2022 | 7.74 | 35.42% |
| 2021 | 5.71 | 46.44% |
| 2020 | 3.90 | 49.21% |
| 2019 | 2.62 | -33.09% |
| 2018 | 3.91 | -16.35% |
| 2017 | 4.67 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 40.53 | 133.02% |
US
|
|
| 38.50 | 121.34% |
US
|
|
| 79.88 | 359.27% |
US
|
|
| 116.96 | 572.46% |
US
|
|
| 22.25 | 27.92% |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.